JP2024520481A5 - - Google Patents
Info
- Publication number
- JP2024520481A5 JP2024520481A5 JP2023573047A JP2023573047A JP2024520481A5 JP 2024520481 A5 JP2024520481 A5 JP 2024520481A5 JP 2023573047 A JP2023573047 A JP 2023573047A JP 2023573047 A JP2023573047 A JP 2023573047A JP 2024520481 A5 JP2024520481 A5 JP 2024520481A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- cycloalkyl
- haloalkyl
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193990P | 2021-05-27 | 2021-05-27 | |
| US63/193,990 | 2021-05-27 | ||
| PCT/US2022/031141 WO2022251502A1 (en) | 2021-05-27 | 2022-05-26 | Checkpoint kinase 1 (chk1) inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520481A JP2024520481A (ja) | 2024-05-24 |
| JP2024520481A5 true JP2024520481A5 (enExample) | 2025-06-02 |
Family
ID=84229213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023573047A Pending JP2024520481A (ja) | 2021-05-27 | 2022-05-26 | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11707462B2 (enExample) |
| EP (1) | EP4347582A4 (enExample) |
| JP (1) | JP2024520481A (enExample) |
| KR (1) | KR20240021188A (enExample) |
| CN (1) | CN117715905A (enExample) |
| AU (1) | AU2022282384A1 (enExample) |
| BR (1) | BR112023024571A2 (enExample) |
| CA (1) | CA3219348A1 (enExample) |
| IL (1) | IL308759A (enExample) |
| MX (1) | MX2023014028A (enExample) |
| TW (1) | TW202313588A (enExample) |
| WO (1) | WO2022251502A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023002453A2 (pt) | 2020-08-12 | 2023-05-02 | Boundless Bio Inc | Composições de agente de via de estresse de replicação e métodos para tratar câncer |
| MX2023006364A (es) * | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| EP4347582A4 (en) | 2021-05-27 | 2025-05-07 | Boundless Bio, Inc. | CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF |
| CA3241992A1 (en) * | 2021-12-24 | 2023-06-29 | Seiji Kamioka | 1h-pyrazole-3-amine derivative having bicyclic backbone |
| CN119546588A (zh) * | 2022-05-24 | 2025-02-28 | 无界生物公司 | 吡啶检查点激酶1（chk1）抑制剂及其用途 |
| CN119255990A (zh) * | 2022-05-25 | 2025-01-03 | 曙方医药 | 作为检查点激酶1抑制剂的含氮五元杂环衍生物及其用途 |
| EP4626433A1 (en) * | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| TW202440549A (zh) * | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| EP4683635A1 (en) * | 2023-03-20 | 2026-01-28 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| JP2026513823A (ja) * | 2023-04-03 | 2026-05-01 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤の結晶形態およびその使用 |
| US20260232659A1 (en) * | 2023-04-03 | 2026-08-13 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
| EP4753712A1 (en) * | 2023-08-02 | 2026-06-10 | Health Research, Inc. | Sequential treatment method for p53-deficient cancer |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026108769A1 (en) | 2024-11-19 | 2026-05-28 | Groovy Medicine (Hangzhou) Ltd. | Substituted 2- [ (5-cyanopyrazin-2-yl) amino] pyridines, their prodrugs and uses thereof |
| WO2026108771A2 (en) | 2024-11-19 | 2026-05-28 | Groovy Medicine (Hangzhou) Ltd. | Substituted heteroaromatic compounds as inhibitors of checkpoint kinase 1 and notch signaling pathway and uses thereof |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
| CN122031724A (zh) * | 2026-04-17 | 2026-05-15 | 中国科学院杭州医学研究所 | 编码p16蛋白的mRNA在制备用于治疗胰腺癌的药物中的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0110302A (pt) * | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
| DZ3398A1 (fr) * | 2000-08-31 | 2002-03-07 | Pfizer Prod Inc | Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CA3013514C (en) * | 2016-02-04 | 2021-11-23 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
| KR20220042159A (ko) * | 2019-08-01 | 2022-04-04 | 인테그랄 바이오사이언스 피브이티. 엘티디. | 키나제 억제제로서의 헤테로사이클릭 화합물 및 이의 용도 |
| CN112457306A (zh) * | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| CN111253370B (zh) | 2020-03-24 | 2021-08-03 | 浙江大学 | N-多取代吡啶-2-氨基嘧啶类衍生物及用途 |
| EP4741018A3 (en) * | 2020-06-19 | 2026-07-15 | Anaxis Pharma Pty Ltd | Sulphonamide compounds |
| BR112023002453A2 (pt) | 2020-08-12 | 2023-05-02 | Boundless Bio Inc | Composições de agente de via de estresse de replicação e métodos para tratar câncer |
| WO2022087326A1 (en) | 2020-10-23 | 2022-04-28 | Celgene Corporation | Heterocyclic compounds and their use for treatment of helminthic infections and diseases |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| MX2023006364A (es) * | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| EP4347582A4 (en) | 2021-05-27 | 2025-05-07 | Boundless Bio, Inc. | CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF |
| CA3241992A1 (en) | 2021-12-24 | 2023-06-29 | Seiji Kamioka | 1h-pyrazole-3-amine derivative having bicyclic backbone |
| CN119546588A (zh) | 2022-05-24 | 2025-02-28 | 无界生物公司 | 吡啶检查点激酶1（chk1）抑制剂及其用途 |
| CN119255990A (zh) | 2022-05-25 | 2025-01-03 | 曙方医药 | 作为检查点激酶1抑制剂的含氮五元杂环衍生物及其用途 |
| JPWO2023229032A1 (enExample) | 2022-05-27 | 2023-11-30 | ||
| TW202440549A (zh) | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| EP4626433A1 (en) | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| EP4683635A1 (en) | 2023-03-20 | 2026-01-28 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| JP2026513823A (ja) | 2023-04-03 | 2026-05-01 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤の結晶形態およびその使用 |
| US20260232659A1 (en) | 2023-04-03 | 2026-08-13 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
-
2022
- 2022-05-26 EP EP22812165.3A patent/EP4347582A4/en active Pending
- 2022-05-26 MX MX2023014028A patent/MX2023014028A/es unknown
- 2022-05-26 BR BR112023024571A patent/BR112023024571A2/pt unknown
- 2022-05-26 WO PCT/US2022/031141 patent/WO2022251502A1/en not_active Ceased
- 2022-05-26 TW TW111119737A patent/TW202313588A/zh unknown
- 2022-05-26 IL IL308759A patent/IL308759A/en unknown
- 2022-05-26 CA CA3219348A patent/CA3219348A1/en active Pending
- 2022-05-26 KR KR1020237044236A patent/KR20240021188A/ko active Pending
- 2022-05-26 CN CN202280052765.2A patent/CN117715905A/zh active Pending
- 2022-05-26 AU AU2022282384A patent/AU2022282384A1/en not_active Abandoned
- 2022-05-26 JP JP2023573047A patent/JP2024520481A/ja active Pending
- 2022-08-29 US US17/897,667 patent/US11707462B2/en active Active
-
2023
- 2023-06-01 US US18/327,775 patent/US12527790B2/en active Active